Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

IMPACT OF GLUCOCORTICOID TREATMENT IN SARS-COV-2 INFECTION MORTALITY: A RETROSPECTIVE CONTROLLED COHORT STUDY

View ORCID ProfileAna Fernández Cruz, View ORCID ProfileBelén Ruiz-Antorán, Ana Muñoz Gómez, View ORCID ProfileAránzazu Sancho López, Patricia Mills Sánchez, Gustavo Adolfo Centeno Soto, Silvia Blanco Alonso, Laura Javaloyes Garachana, Amy Galán Gómez, Ángela Valencia Alijo, Javier Gómez Irusta, Concepción Payares-Herrera, Ignacio Morrás Torre, Enrique Sánchez Chica, Laura Delgado Téllez de Cepeda, Alejandro Callejas Díaz, View ORCID ProfileAntonio Ramos Martínez, Elena Múñez Rubio, View ORCID ProfileCristina Avendaño-Solá
doi: https://doi.org/10.1101/2020.05.22.20110544
Ana Fernández Cruz
1Infectious Diseases Unit, Internal Medicine Department, Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ana Fernández Cruz
  • For correspondence: anafcruz999@gmail.com
Belén Ruiz-Antorán
2Clinical Pharmacology Department, Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Belén Ruiz-Antorán
  • For correspondence: bruizantoran@gmail.com
Ana Muñoz Gómez
3Internal Medicine Department, Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aránzazu Sancho López
2Clinical Pharmacology Department, Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Aránzazu Sancho López
Patricia Mills Sánchez
3Internal Medicine Department, Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gustavo Adolfo Centeno Soto
2Clinical Pharmacology Department, Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Silvia Blanco Alonso
3Internal Medicine Department, Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura Javaloyes Garachana
2Clinical Pharmacology Department, Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amy Galán Gómez
3Internal Medicine Department, Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ángela Valencia Alijo
3Internal Medicine Department, Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Javier Gómez Irusta
3Internal Medicine Department, Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Concepción Payares-Herrera
2Clinical Pharmacology Department, Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ignacio Morrás Torre
3Internal Medicine Department, Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Enrique Sánchez Chica
3Internal Medicine Department, Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura Delgado Téllez de Cepeda
4Pharmacy Department, Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigation Sanitaria Puerta de Hierro - Segovia de Arana, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alejandro Callejas Díaz
1Infectious Diseases Unit, Internal Medicine Department, Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antonio Ramos Martínez
1Infectious Diseases Unit, Internal Medicine Department, Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana, Madrid, Spain
4Pharmacy Department, Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigation Sanitaria Puerta de Hierro - Segovia de Arana, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Antonio Ramos Martínez
Elena Múñez Rubio
1Infectious Diseases Unit, Internal Medicine Department, Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cristina Avendaño-Solá
2Clinical Pharmacology Department, Hospital Universitario Puerta de Hierro-Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Cristina Avendaño-Solá
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Objective We aim to determine the impact of steroid use in COVID-19 pneumonia in-hospital mortality.

Design We performed a single-centre retrospective cohort study.

Setting A University hospital in Madrid, Spain, during March 2020.

Participants Patients admitted with SARS-CoV-2 pneumonia.

Exposures Patients treated with steroids were compared to patients not treated with steroids. A propensity-score for steroid treatment was developed. Different steroid regimens were also compared, and adjusted with a second propensity score.

Main Outcomes and Measures To determine the role of steroids in in-hospital mortality, univariable and multivariable analyses were performed, and adjusted including the propensity score as a covariate. Survival times were compared using a log-rank test.

Results During the study period, 463 out of 848 hospitalized patients with COVID19 pneumonia fulfilled inclusion criteria. Among them, 396 (46.7%) consecutive patients were treated with steroids and 67 patients were assigned to the control cohort. Global mortality was 15.1%. Median time to steroid treatment from symptom onset was 10 days (IQR 8 to13). In-hospital mortality was lower in patients treated with steroids than in controls (13.9% [55/396] versus 23.9% [16/67], OR 0.51 [0.27 to 0.96], p= 0.044). Steroid treatment reduced mortality by 41.8% relative to no steroid treatment (RRR 0,42 [0.048 to 0.65). Initial treatment with 1 mg/kg/day of methylprednisolone (or equivalent) versus steroid pulses was not associated with in-hospital mortality (13.5% [42/310] versus 15.1% [13/86], OR 0.880 [0.449-1.726], p=0.710).

Conclusions Our results show that survival of patients with SARS-CoV2 pneumonia is higher in patients treated with glucocorticoids than in those not treated. In-hospital mortality was not different between initial regimens of 1 mg/kg/day of methylprednisolone or equivalent and glucocorticoid pulses. These results support the use of glucocorticoids in SARS-CoV2 infection.

Summary We investigated in-hospital mortality of patients with SARS-CoV-2 pneumonia in a large series of patients treated with steroids compared to controls, and adjusted using a propensity score. Our results show a beneficial impact of steroid treatment in SARS-CoV-2 pneumonia.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Protocols

http://www.encepp.eu/encepp/studySearch.htm

Funding Statement

The study did not receive any funding.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Institutional Review Board (CEIm) at Hospital Universitario Puerta de Hierro Majadahonda (BRA COR 2020 03), and a waiver for the informed consent was granted. The study complied with the provisions in EU and Spanish legislation on data protection and the Declaration of Helsinki 2013.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

After publication, the data will be made available to others on reasonable requests to the corresponding authors. A proposal with a detailed description of study objectives and statistical analysis plan will be needed for evaluation of the reasonability of requests. Additional materials might also be required during the process of evaluation. De-identified participant data will be provided after approval from the principal researchers of the Hospital Puerta de Hierro-Majadahonda.

  • ABBREVIATIONS
    SARS-CoV
    severe acute respiratory syndrome coronavirus
    COVID-19
    coronavirus disease 2019
    Steroids
    glucocorticoids or corticoids
    OR
    Odds ratio
    MERS-CoV
    Middle east respiratory syndrome coronavirus
    PaO2/FiO2
    arterial oxygen tension/inspiratory oxygen fraction
    CT
    computed tomography
    ARDS
    acute respiratory distress syndrome
    CRP
    C-reactive protein
    PEEP
    positive end expiratory pressure
    SD
    standard deviation
    CI
    confidence interval
    PSM
    propensity-score matching
    RRR
    relative risk reduction
    NNT
    number necessary to treat
    HR
    hazard ratio
    IQR
    interquartile range
    COPD
    chronic obstructive pulmonary disease
    LDH
    Lactate dehydrogenase
    SpO2
    plasma oxygen saturation
    ICU
    Intensive care Unit
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
    Back to top
    PreviousNext
    Posted May 26, 2020.
    Download PDF

    Supplementary Material

    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    IMPACT OF GLUCOCORTICOID TREATMENT IN SARS-COV-2 INFECTION MORTALITY: A RETROSPECTIVE CONTROLLED COHORT STUDY
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    IMPACT OF GLUCOCORTICOID TREATMENT IN SARS-COV-2 INFECTION MORTALITY: A RETROSPECTIVE CONTROLLED COHORT STUDY
    Ana Fernández Cruz, Belén Ruiz-Antorán, Ana Muñoz Gómez, Aránzazu Sancho López, Patricia Mills Sánchez, Gustavo Adolfo Centeno Soto, Silvia Blanco Alonso, Laura Javaloyes Garachana, Amy Galán Gómez, Ángela Valencia Alijo, Javier Gómez Irusta, Concepción Payares-Herrera, Ignacio Morrás Torre, Enrique Sánchez Chica, Laura Delgado Téllez de Cepeda, Alejandro Callejas Díaz, Antonio Ramos Martínez, Elena Múñez Rubio, Cristina Avendaño-Solá
    medRxiv 2020.05.22.20110544; doi: https://doi.org/10.1101/2020.05.22.20110544
    Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
    Citation Tools
    IMPACT OF GLUCOCORTICOID TREATMENT IN SARS-COV-2 INFECTION MORTALITY: A RETROSPECTIVE CONTROLLED COHORT STUDY
    Ana Fernández Cruz, Belén Ruiz-Antorán, Ana Muñoz Gómez, Aránzazu Sancho López, Patricia Mills Sánchez, Gustavo Adolfo Centeno Soto, Silvia Blanco Alonso, Laura Javaloyes Garachana, Amy Galán Gómez, Ángela Valencia Alijo, Javier Gómez Irusta, Concepción Payares-Herrera, Ignacio Morrás Torre, Enrique Sánchez Chica, Laura Delgado Téllez de Cepeda, Alejandro Callejas Díaz, Antonio Ramos Martínez, Elena Múñez Rubio, Cristina Avendaño-Solá
    medRxiv 2020.05.22.20110544; doi: https://doi.org/10.1101/2020.05.22.20110544

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Infectious Diseases (except HIV/AIDS)
    Subject Areas
    All Articles
    • Addiction Medicine (62)
    • Allergy and Immunology (144)
    • Anesthesia (47)
    • Cardiovascular Medicine (419)
    • Dentistry and Oral Medicine (72)
    • Dermatology (49)
    • Emergency Medicine (147)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (174)
    • Epidemiology (4906)
    • Forensic Medicine (3)
    • Gastroenterology (185)
    • Genetic and Genomic Medicine (689)
    • Geriatric Medicine (72)
    • Health Economics (193)
    • Health Informatics (636)
    • Health Policy (322)
    • Health Systems and Quality Improvement (209)
    • Hematology (86)
    • HIV/AIDS (157)
    • Infectious Diseases (except HIV/AIDS) (5408)
    • Intensive Care and Critical Care Medicine (333)
    • Medical Education (96)
    • Medical Ethics (24)
    • Nephrology (77)
    • Neurology (692)
    • Nursing (42)
    • Nutrition (115)
    • Obstetrics and Gynecology (128)
    • Occupational and Environmental Health (211)
    • Oncology (447)
    • Ophthalmology (140)
    • Orthopedics (36)
    • Otolaryngology (91)
    • Pain Medicine (37)
    • Palliative Medicine (18)
    • Pathology (131)
    • Pediatrics (201)
    • Pharmacology and Therapeutics (131)
    • Primary Care Research (88)
    • Psychiatry and Clinical Psychology (787)
    • Public and Global Health (1832)
    • Radiology and Imaging (328)
    • Rehabilitation Medicine and Physical Therapy (142)
    • Respiratory Medicine (257)
    • Rheumatology (87)
    • Sexual and Reproductive Health (69)
    • Sports Medicine (63)
    • Surgery (102)
    • Toxicology (23)
    • Transplantation (29)
    • Urology (38)